LSD

• Description:

  LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics[1].

• UNSPSC:

  12352209

• Target:

  Biochemical Assay Reagents

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lsd.html

• Purity:

  98.11

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CS)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CS)N

• Molecular Formula:

  C39H72N14O13S2

• Molecular Weight:

  1009.20

• References & Citations:

  [1]Zhang L, et al. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res. 2006 Jun 1;66 (11) :5696-706.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 2

• CAS Number:

  [945245-76-1]